PEKKIP Oncology Alliance AG

Biotechnology - Therapeutics and Diagnostics

proteona.png

PEKKIP Oncology AG aims to improve the quality of life of cancer patients and to extend their lives with novel, innovative and affordable medicines addressing specific unmet medical needs. PEKKIP Oncology AG is a privately-owned, oncology research and early development company founded in 2014 in Heidelberg with a global reach. PEKKIP has built close partnerships with top universities research lab, oncology research centers and KOL’s to develop innovative, novel treatments of cancer with improved tolerability. PEKKIP seeks the best pharma partners to complete the development of these promising compounds and to rapidly bring them to patients.
FUBIS is its first drug against bone metastases to enter clinical development within 2019 and has shown promising results in pre-clinical settings.